NCT06094491

Brief Summary

The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
720

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 17, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 23, 2023

Completed
6 months until next milestone

Study Start

First participant enrolled

May 3, 2024

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Completed
Last Updated

July 8, 2026

Status Verified

July 1, 2026

Enrollment Period

2.2 years

First QC Date

October 17, 2023

Last Update Submit

July 7, 2026

Conditions

Keywords

virtual group visits

Outcome Measures

Primary Outcomes (1)

  • A1c

    This is blood test that measures the percent of glucose and hemoglobin bound together.

    12 months

Secondary Outcomes (3)

  • Systolic blood pressure

    12 months

  • Body Mass Index

    12 months

  • Low density lipoproteins

    12 months

Study Arms (2)

Virtual Group Visit Arm

EXPERIMENTAL

These subjects will attend 6 monthly virtual group visits hosted by ACCESS or Advocate research staff.

Behavioral: Virtual Group Visit

Usual Care Arm

NO INTERVENTION

These subjects will receive usual diabetes care at ACCESS or Advocate health centers.

Interventions

Group visits must have these core components: diabetes education, group social support and goal setting.

Virtual Group Visit Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient at a PARTICIPATING clinic (at least one visit in year prior to first GV)
  • Type 2 diabetes
  • ≥ 18 years old
  • A1C\>8% within 6 months prior to first GV (we will first recruit patients with A1C\>9%, then if spaces still available A1C\>8.5%, then if spaces still available A1C\>8%)
  • At least one additional cardiovascular condition (hypertension, heart disease, stroke, hyperlipidemia, peripheral vascular disease, or BMI ≥ 30)
  • English or Spanish speaking
  • PCP assented to recruiting patient
  • Patient provides written consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Access Community Health Network

Chicago, Illinois, 60661, United States

Location

Advocate Health Care

Orland Park, Illinois, 60462, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2HypertensionStrokeHyperlipidemiasPeripheral Vascular DiseasesObesity

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesVascular DiseasesCardiovascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDyslipidemiasLipid Metabolism DisordersOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Arshiya Baig, MD

    University of Chicago

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Type I hybrid effectiveness-implementation cluster randomized trial among adult patients with T2DM across 9 intervention sites and 9 control sites
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 17, 2023

First Posted

October 23, 2023

Study Start

May 3, 2024

Primary Completion

June 30, 2026

Study Completion

June 30, 2026

Last Updated

July 8, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations